Effects of SGLT2 inhibitors on the metabolic syndrome and its components

Corresponding author: Zhang zhenwen, yzdxzzw@163.com

DOI: 10.12201/bmr.202503.00002

•  

  Abstract: Metabolic syndrome is a group of interrelated risk factors and can be used as a predictor of diabetes and heart failure. Metabolic disorders such as insulin resistance, chronic oxidative stress, ectopic fat accumulation and abnormal regulation of lipid-related factors are the key components of metabolic syndrome. SGLT2 inhibitors are oral hypoglycemic agents that reduce blood glucose levels and induce body fat loss, which in turn improve the development of diabetic complications such as cardiovascular disease, Steatosis disease and chronic kidney disease. Insulin resistance plays a central role in metabolic syndrome and type 2 diabetes. It has been proved that SGLT2 inhibitor can improve insulin resistance through biochemical and neuroinhibitory pathways, such as glucose toxicity, lipotoxicity and oxidative stress, then reduce weight, regulate blood pressure, reduce blood sugar and improve blood lipids, play a role in regulating metabolism, heart and kidney protection

  Key words: SGLT2 inhibitors; metabolic syndrome; insulin resistance; cardio-renal-metabolic syndrome

  Submit time: 2 March 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• Zhenghaijuan, NiuXiaohan. Research Progress of CCR and metabolic syndrome and its related diseases. 2025. doi: 10.12201/bmr.202501.00048

  JIANG Yunlan, LI Le, CHEN Hong, WANG Jing, ZHANG Mengjie, BAI Xiaoyu, WU Senlin. Risk factors for metabolic syndrome in hospitalized schizophrenia patients in China: a Meta-analysis. 2025. doi: 10.12201/bmr.202504.00071

  Liu Wei, Cao Jun, Zhang Xiao Mei, Wang Bao Hua, Zhu Hong Qing. Effects of Shugan Huoxue Yishen decoction on homocysteine, inflammatory factors and endothelial function in patients with metabolic syndrome-related erectile dysfunction. 2025. doi: 10.12201/bmr.202508.00012

  Zhang Han, Chu Mengyuan, Xu Kaikai, Xiang Xin, Yan Ying. Progress in Mechanism of Action of Isthmin1 Protein in Polycystic Ovary Syndrome. 2024. doi: 10.12201/bmr.202411.00004

  Wangzhong. Correlation of Serum soluble TREM2 with Acute coronary syndrome in the elderly. 2024. doi: 10.12201/bmr.202412.00086

  WANG Ziqian, SUN Xiuquan, LI Xiaoqian, MENG Limin. Effect of Preoperative Diltiazem Administration on Coronary Microcirculation and Vascular Endothelial Function in Patients with Acute Coronary Syndrome. 2025. doi: 10.12201/bmr.202506.00082

  WU Xiayang. The mechanisms of action of SGLT2i in the treatment of heart failure and recent research advances. 2025. doi: 10.12201/bmr.202507.00052

  XuHong. Advances in the treatment of osteopenia-seropathic obesity syndrome in the elderly. 2024. doi: 10.12201/bmr.202411.00064

  TANG Shishi, ZHOU Yi. Research on Hemorrhagic Fever with Renal Syndrome Incidence Prediction Based on the SARIMA-LSTM Model. 2024. doi: 10.12201/bmr.202407.00046

  Liu Lingyan. Ferroptosis and endoplasmic reticulum stress in polycystic ovary syndrome and related potential therapeutic targets. 2025. doi: 10.12201/bmr.202507.00042

• ID	Submit time	Number	Download
  1	2024-12-28	10.12201/bmr.202503.00002V1	Download

• Public  Anonymous  To author only Submit Comments